ArticleScientific reports2015
Serological Measures of Trachoma Transmission Intensity.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial.JAMA network open · 2022Trial
- Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo.Scientific reports · 2021Trial
- Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger.PLoS neglected tropical diseases · 2019Trial
- Comparison of three serological assays to measure antibody response to Chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease.International journal of STD & AIDS · 2018Trial
- Comparison of Methods for Assessing Chlamydia trachomatis Transmission Intensity: A Systematic Review.The American journal of tropical medicine and hygiene · 2026Article
- Dynamics of trachoma infection in West Africa revealed by a hidden state model.PLoS computational biology · 2026Article
- Does persistent active trachoma mandate antibiotic mass drug administration? A comparison of prevalence of trachomatous inflammation-follicular with that of conjunctival infection and anti-chlamydial antibodies, Western Province, Zambia.International health · 2026Article
- Monitoring of Chlamydia trachomatis infection and antibodies in low-prevalence districts of Amhara, Ethiopia: Insights from a hyper-endemic trachoma region.PLoS neglected tropical diseases · 2026Article
- Assessing trachoma elimination progress in districts with persistent trachoma, Western Province, Zambia.International health · 2025Article
- Cost-effectiveness of adding measurement of Chlamydia trachomatis infection and serology to trachoma prevalence surveys in Tanzania and Mozambique.PLoS neglected tropical diseases · 2025Article
- Ongoing transmission of trachoma in low prevalence districts in Mozambique: results from four cross-sectional enhanced impact surveys, 2022.Scientific reports · 2024Article
- Wastewater surveillance beyond COVID-19: a ranking system for communicable disease testing in the tri-county Detroit area, Michigan, USA.Frontiers in public health · 2023Article
- Clinical signs of trachoma and laboratory evidence of ocular Chlamydia trachomatis infection in a remote Queensland community: a serial cross-sectional study.The Medical journal of Australia · 2022Article
- Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts' meeting on serum biomarkers.PLoS neglected tropical diseases · 2022Article
- Seroprevalence of Chlamydia trachomatis Among Female Adults in the United States: The National Health and Nutrition Examination Surveys.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- The use of serology for trachoma surveillance: Current status and priorities for future investigation.PLoS neglected tropical diseases · 2020Review
- Trachoma Prevalence After Discontinuation of Mass Azithromycin Distribution.The Journal of infectious diseases · 2020Article
- Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma.The Journal of infection · 2020Article
- Insights from mathematical modelling and quantitative analysis on the proposed 2030 goals for trachoma.Gates open research · 2019Article
- The utility of serology for elimination surveillance of trachoma.Nature communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular infection with Chlamydia trachomatis can lead to trachoma, a leading infectious cause of blindness. Trachoma is targeted for elimination by 2020. Clinical grading for ocular disease is currently used for evaluating trachoma elimination programs, but serological surveillance can be a sensitive measure of disease transmission and provide a more objective testing strategy than clinical grading. We calculated the basic reproduction number from serological data in settings with high, medium, and low disease transmission based on clinical disease. The data showed a striking relationship between age seroprevalence and clinical data, demonstrating the proof-of-principle that age seroprevalence predicts transmission rates and therefore could be used as an indicator of decreased transmission of ocular trachoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.